Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • Anti-InflammatoryClosed to enrollment Location: USA

    KB001-A in people with CF and Pseudomonas aeruginosa , protocol number KaloBios KB001-05

    This study took place at multiple care centres across the U.S. It looked to see whether the use of KB001A in people with CF who have Pseudomonas aeruginosa delays the need for antibiotic drugs.

    • Age:

      12-50 Years

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-100%

    • Number of Visits:

      10

    • Length of Participation:

      20 weeks

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis , protocol number NARKEW07A0

    This study will look at whether using abdominal ultrasounds predicts the progression of liver disease in children with CF.

    • Age:

      3 Years to 12 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      5

    • Length of Participation:

      5 years

    Contact us about this clinical Trial >
  • ObservationalClosed to enrollment Location: USA

    Genetic Modifiers of Cystic Fibrosis: Sibling Study , protocol number NCT00037778

    The purpose of the study was to find genetic and environmental factors effecting the variability in nutritional outcomes seen in people with CF.

    • Age:

      No age limit

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      0

    • Length of Participation:

      0

    Contact us about this clinical Trial >
  • Anti-InflammatoryEnrolling Location: Multiple care centres across the US

    Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number NCT03265288

    This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and it will use a placebo control.

    • Age:

      12 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      50-90%

    • Number of Visits:

      6

    • Length of Participation:

      189 days

    Contact us about this clinical Trial >
  • Anti-InfectiveCompleted with results Location: USA

    OPTIMIZE: Phase 3 study of tobramycin solution for inhalation with and without azithromycin , protocol number NCT02054156 OPTIMIZE-IP-12

    This study is taking place at multiple care centers across the US. It will compare the effects of treatment with tobramycin solution for inhalation with and without azithromycin. It is for people with CF who have their first isolation of Pseudomonas aeruginosa from a respiratory culture.

    • Age:

      6 Months to 18 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 limit

    • Number of Visits:

      8

    • Length of Participation:

      18 months

    Contact us about this clinical Trial >
  • Restore CFTR FunctionCompleted with results Location: USA

    Phase 1b safety study of QR-010 in adults with CF , protocol number NCT02532764 PRO QR PQ-010-001

    This study evaluated the safety and tolerability of the inhaled drug eluforsen in people with CF who have two copies of the F508del CFTR mutation.

    • Age:

      18 Years and to 60 Years

    • Mutation(s):

      Two copies F508del

    • FEV1% Predicted:

      70% or greater

    • Number of Visits:

      10

    • Length of Participation:

      8 weeks

    Contact us about this clinical Trial >
  • ObservationalCompleted with results Location: USA

    PROSPECT , protocol number PROSPECT-OB-14

    This two-part study is taking place at multiple care centres across the US. It will aim to identify biomarkers that show CFTR function and disease progression. It will also look at the effect of lumacafter/ivacaftor on those who are prescribed treatment.

    • Age:

      6 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      8

    • Length of Participation:

      15 months

    Contact us about this clinical Trial >
  • Mucociliary ClearanceClosed to enrollment Location: USA

    Clearing Lungs With ENAC Inhibition in Cystic Fibrosis (CLEAN-CF) , protocol number Parion PS-G201

    This trail will look at the safety of the drug P-1037 and its effectiveness in combination with the drug hypertonic saline. The trail is estimated to last 5 weeks. It is for people with CF age 12 years and older.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      40 to 90%

    • Number of Visits:

      4

    • Length of Participation:

      5 weeks

    Contact us about this clinical Trial >
  • Anti-InfectiveClosed to enrollment Location: USA

    AeroVanc for the treatment of MRSA in people with CF , protocol number Savara SAV005-02

    This study took place at multiple care centres across the US. It looked at the safety and effectiveness of AeroVanc in treating persistent MRSA lung infections in people with cystic fibrosis.

    • Age:

      12 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30 to 100%

    • Number of Visits:

      9

    • Length of Participation:

      16 weeks

    Contact us about this clinical Trial >
  • Mucociliary ClearanceCompleted with results Location: USA

    SHIP: Study of hypertonic saline in preschoolers , protocol number NCT02378467 SHIP01

    This SHIP study evaluated the safety and effectiveness of hypertonic saline (7%) in pre-school children with CF.

    • Age:

      3 Years to 5 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      Less than 99%

    • Number of Visits:

      6

    • Length of Participation:

      54 weeks

    Contact us about this clinical Trial >
  • Displaying results 141-150 (of 178)
     |<  <  9 - 10 - 11 - 12 - 13 - 14 - 15 - 16 - 17 - 18  >  >|